{{Drugbox
| Watchedfields = changed
| verifiedrevid = 443275125
| IUPAC_name = 5-amino-2-[2-(dimethylamino)ethyl]-1''H''-benzo[''de'']isoquinoline-1,3(2''H'')-dione
| image = Amonafide.svg

<!--Clinical data-->
| tradename = Xanafide, Quinamed
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL, P, POM, CD, or Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number = 69408-81-7
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 50515
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 45804
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 1Q8D39N37L
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 428676
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D10090

<!--Chemical data-->
| C=16 | H=17 | N=3 | O=3 
| molecular_weight = 283.325 g/mol
| smiles = O=C2c1c3c(ccc1)cc(cc3C(=O)N2CCN(C)C)N
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C16H17N3O2/c1-18(2)6-7-19-15(20)12-5-3-4-10-8-11(17)9-13(14(10)12)16(19)21/h3-5,8-9H,6-7,17H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = UPALIKSFLSVKIS-UHFFFAOYSA-N
}}
'''Amonafide''' (originally AS1413) ([[International Nonproprietary Name|INN]], trade names '''Quinamed''' and '''Xanafide''') is a drug that is being studied in the treatment of [[cancer]]. It belongs to a novel family of chemotherapeutic drugs called Naphthalimides and is a potential [[topoisomerase inhibitor]] and [[DNA intercalator]].

It is being developed as an anti-cancer therapy by [[Antisoma]].<ref>http://www.genengnews.com/news/bnitem.aspx?name=78979622</ref>

{{As of|2008}}, it is in [[clinical trial#Phase III|Phase III]] [[clinical trial]]s.
e.g. In March 2010 it is [[Phase III]] trial against secondary [[acute myeloid leukaemia]] (AML).<ref>http://clinicaltrials.gov/ct2/show/NCT00715637 "Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCEDE Study"</ref> In June 2010, it gained an FDA Fast Track Status for the treatment of Secondary Acute Myeloid Leukaemia.
==See also==
*[[Alrestatin]]
==References==
{{reflist}}

== External links ==
* [http://www.cancer.gov/dictionary?CdrID=350223 Amonafide] entry in the public domain NCI Dictionary of Cancer Terms
* [http://www.clinicaltrials.gov/ct2/results?term=amonafide Clinical trials of amonafide] at ClinicalTrials.gov

{{NCI-cancer-dict}}

[[Category:Experimental cancer drugs]]


{{antineoplastic-drug-stub}}